The decision makes pembrolizumab the second PD-1-blocking drug to receive approval in Europe.
July 22, 2015
The trial was stopped early because data showed that patients lived longer on nivolumab compared to the standard-of-care drug.
July 20, 2015
Raise a flag in honor of someone affected by cancer and help us win a $75,000 donation.
July 13, 2015